Pharma and life sciences
Agents do the work. A named person signs.
Agent output is reviewed and signed by a named person, as the FDA's April 2026 warning letter (320-26-58) requires of the quality unit. Every signature lands in an audit trail your inspector checks offline.
Built for 21 CFR Part 11, EU Annex 11 and draft Annex 22.